DeepSyte matches this bill to the issues you care about and shows whether your reps' votes line up — not party, not press releases. Take the 2-minute values quiz to see your alignment.
Sign in and take the values quiz to see how this bill lines up with what you've said.
The Medical Innovation Act of 2024 authorizes the federal government to assess supplemental payments from pharmaceutical manufacturers that have entered into settlement agreements for violations of federal law and produce blockbuster drugs (with over $1 billion in annual sales) developed using federally-funded research. The payment amount ranges from 0.75% to 1.5% of the manufacturer's net income, multiplied by the number of qualifying drugs, with collected funds directed to increase congressional investments in medical research. The bill establishes procedures for identifying covered manufacturers, publishing payment information, and collecting these supplemental payments annually.
Sign in and take the values quiz to get a personalized read on how this bill lines up with your positions.
Sign in to see how your representatives voted on this bill.